Literature DB >> 29197461

Ineffective and prolonged apical contraction is associated with chest pain and ischaemia in apical hypertrophic cardiomyopathy.

Edward Stephenson1, Pierre Monney2, Francesca Pugliese3, James Malcolmson3, Steffen E Petersen3, Charles Knight3, Peter Mills4, Andrew Wragg3, Constantinos O'Mahony4, Neha Sekhri3, Saidi A Mohiddin5.   

Abstract

OBJECTIVES: To investigate the hypothesis that persistence of apical contraction into diastole is linked to reduced myocardial perfusion and chest pain.
BACKGROUND: Apical hypertrophic cardiomyopathy (HCM) is defined by left ventricular (LV) hypertrophy predominantly of the apex. Hyperdynamic contractility resulting in obliteration of the apical cavity is often present. Apical HCM can lead to drug-refractory chest pain.
METHODS: We retrospectively studied 126 subjects; 76 with apical HCM and 50 controls (31 with asymmetrical septal hypertrophy (ASH) and 19 with non-cardiac chest pain and culprit free angiograms and structurally normal hearts). Perfusion cardiac magnetic resonance imaging (CMR) scans were assessed for myocardial perfusion reserve index (MPRi), late gadolinium enhancement (LGE), LV volumes (muscle and cavity) and regional contractile persistence (apex, mid and basal LV).
RESULTS: In apical HCM, apical MPRi was lower than in normal and ASH controls (p<0.05). In apical HCM, duration of contractile persistence was associated with lower MPRi (p<0.01) and chest pain (p<0.05). In multivariate regression, contractile persistence was independently associated with chest pain (p<0.01) and reduced MPRi (p<0.001).
CONCLUSION: In apical HCM, regional contractile persistence is associated with impaired myocardial perfusion and chest pain. As apical myocardium makes limited contributions to stroke volume, apical contractility is also largely ineffective. Interventions to reduce apical contraction and/or muscle mass are potential therapies for improving symptoms without reducing cardiac output.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CMR; Cardiac magnetic resonance; Hypertrophic cardiomyopathy; Perfusion

Mesh:

Year:  2018        PMID: 29197461     DOI: 10.1016/j.ijcard.2017.09.206

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Usefulness of ECG to differentiate apical hypertrophic cardiomyopathy from non-ST elevation acute coronary syndrome.

Authors:  Yirao Tao; Jing Xu; Samira Yerima Bako; Xiaobo Yao; Donghui Yang
Journal:  BMC Cardiovasc Disord       Date:  2020-06-23       Impact factor: 2.298

2.  Apical Hypertrophic Cardiomyopathy: The Variant Less Known.

Authors:  Rebecca K Hughes; Kristopher D Knott; James Malcolmson; João B Augusto; Saidi A Mohiddin; Peter Kellman; James C Moon; Gabriella Captur
Journal:  J Am Heart Assoc       Date:  2020-02-28       Impact factor: 5.501

3.  Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy.

Authors:  James W Malcolmson; Rebecca K Hughes; Abhishek Joshi; Jackie Cooper; Alexander Breitenstein; Matthew Ginks; Steffen E Petersen; Saidi A Mohiddin; Mehul B Dhinoja
Journal:  Ther Adv Cardiovasc Dis       Date:  2022 Jan-Dec

4.  Inline perfusion mapping provides insights into the disease mechanism in hypertrophic cardiomyopathy.

Authors:  Claudia Camaioni; Kristopher D Knott; Joao B Augusto; Andreas Seraphim; Stefania Rosmini; Fabrizio Ricci; Redha Boubertakh; Hui Xue; Rebecca Hughes; Gaby Captur; Luis Rocha Lopes; Louise Anne Elizabeth Brown; Charlotte Manisty; Steffen Erhard Petersen; Sven Plein; Peter Kellman; Saidi A Mohiddin; James C Moon
Journal:  Heart       Date:  2019-12-10       Impact factor: 5.994

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.